Syndax Reports Phase 2 Setback For Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals (SNDX) reported that its Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The drug was well tolerated, and the company will not advance it for IPF but will continue trials in other indications. SNDX stock fell 2.59% on Monday and is down 16.07% in overnight trading.
How this was made
The 30-second read
Why it matters
The failure may delay or reduce future cash flow expectations and could affect upcoming partnership talks.
Market read
First‑report of a Phase 2 setback for a small‑cap biotech, likely prompting short‑term sell pressure.
What to watch
The trial's safety profile was favorable, which could support future programs despite efficacy miss.
Background
Syndax's axatilimab is already approved for chronic graft‑versus‑host disease; the IPF trial was a separate indication.
Ticker impact
Syndax announced its Phase 2 MAXPIRe trial of axatilimab in IPF failed to meet the primary endpoint.
likely pressure as the market prices in the failed trial data
Phase 2 failure reduces near‑term revenue expectations and may delay further development milestones.
Market effects
Biotech and pharma stocks may see broader caution on early‑stage trial outcomes.
US biotech sector could experience modest sell pressure.
Limited to companies developing CSF‑1R antibodies and related therapies.
Counterpoint
If the company can pivot axatilimab to other indications, the long‑term impact may be muted.
Key entities
- companySyndax Pharmaceuticals Inc.
US‑listed biotech developing axatilimab.
